Target-Based Resistance in Pseudomonas aeruginosa and Escherichia coli to NBTI 1 5463 , a Novel Bacterial Type II Topoisomerase Inhibitor 2 3 4 5

1 5463, a Novel Bacterial Type II Topoisomerase Inhibitor 2 3 4 5 Asha S. Nayar, Thomas J. Dougherty1, Folkert Reck2, Jason Thresher, Ning Gao, Adam 6 B. Shapiro, and David E. Ehmann# 7 8 9 Infection Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, 10 Massachusetts, USA 11 12 13 #Corresponding author: David E. Ehmann (david.ehmann@astrazeneca.com) 14 15 Running title: Resistance to a novel topoisomerase inhibitor 16 17 18 19 1. present address: Thomas J. Dougherty, Department of Microbiology & 20 Immunobiology, Harvard Medical School, Boston, Massachusetts, USA 21 2. present address: Folkert Reck, Infectious Diseases Area, Novartis Institutes 22 for Biomedical Research, Emeryville, California, USA 23 AAC Accepts, published online ahead of print on 27 October 2014